Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextroamphetamine
- Development stage
- Approved
- Modality
- Small Molecules
- Administration
- Oral, Transdermal
01
Overview
Dextroamphetamine is the dextrorotatory enantiomer of amphetamine and acts as a potent central nervous system stimulant. It is primarily used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Dextroamphetamine increases synaptic concentrations of dopamine, norepinephrine, and serotonin by inhibiting or reversing their transporter proteins (dopamine transporter, norepinephrine transporter, serotonin transporter) via trace amine-associated receptor 1 (TAAR1), and by promoting release from synaptic vesicles through vesicular monoamine transporter 2 (VMAT2). This results in increased alertness, improved focus, reduced impulsivity in ADHD patients, and promotion of wakefulness in narcolepsy. It is available as tablets, extended-release capsules, oral solution, and transdermal patch[1][2][4][5].
- Brand names
- DexedrineDexedrine SpansuleDextrostatLiquaddProCentraZenzediXelstrym
- Other names
- dexamfetaminedexamphetaminedesamfetaminadexanfetamina
02
Targets
SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on dextroamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextroamphetamine.